As the population ages, China will face an ever-increasing burden from CS. Strategies targeting elder population and high-risk groups should be prioritized in the establishment of management related ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results